Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation

Kahn Swick & Foti is investigating the proposed merger of Rallybio Corporation and Avenzo Therapeutics, focusing on whether the transaction and the process leading to it are adequate. Rallybio equityholders before the transaction are expected to own approximately 2.8% of the combined company.

Analysis

The relevant issue is not the existence of an investigation by itself, but whether the merger’s exchange ratio and approval process withstand scrutiny. A law-firm inquiry is not evidence of a deficient process and, absent a court filing or material proxy disclosure, is a weak standalone signal for deal failure. Near term, it can add headline volatility to RLYB; over the next 1–3 months, the meaningful catalysts are the definitive proxy, any competing proposal, shareholder vote, and any request for injunctive relief. The 2.8% expected ownership for legacy Rallybio holders makes transaction valuation and the assets, cash, and dilution contributed by each side central: that ownership percentage alone does not establish whether the exchange is unfair. If the combined company depends on future financing, dilution and runway could matter more to legacy holders than a modest improvement in merger terms. Over 6–18 months, value will be driven primarily by the combined company’s execution and financing needs, not the investigation headline. Verify the merger agreement, fairness materials, capitalization and cash forecasts, and whether the inquiry progresses into litigation. The thesis that this is only procedural noise is falsified by a court order delaying the vote or closing, a material change to terms, or a competing bid.

Key Decisions for Investors

• Do not initiate a directional RLYB position solely on the investigation notice. Treat it as a low-conviction event-risk alert until the proxy and transaction economics are available.
• For existing holders, review the proxy for the exchange mechanics, fairness analysis, pro forma ownership and capitalization, cash runway, and termination provisions; compare the value of the deal with standalone alternatives before voting.
• Monitor for a filed complaint, motion for injunctive relief, vote or closing delay, revised terms, or a competing proposal. These would materially change the probability-weighted deal outcome; a notice without escalation is not a sufficient catalyst.
• Avoid assuming a merger-arbitrage opportunity without the consideration structure, market price, closing conditions, and timing. If those details become available, reassess expected spread against financing, regulatory, and litigation-delay risk.